추천 제품
분석
>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)
형태
powder
포장
pkg of 1 × 100 μg (with stopper and crimp cap (850103P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850103P-500ug))
제조업체/상표
Avanti Research™ - A Croda Brand 850103P
지질 유형
phosphoglycerides
배송 상태
dry ice
저장 온도
−20°C
SMILES string
[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCC/C=C\CCCCCC)=O.[NH4+]
일반 설명
Lysophosphatidylinositol (LPI), a degradation product of phosphatidylinositol (PI) is a lysophospholipid subspecies, which carries inositol in its head group.
애플리케이션
17:1 Lyso PI (1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol)) has been used as an internal standard in LC-MS of mice brain lipidomic analysis. It may be used as internal standard in for the analysis of lysophosphatidylinositols (LPIs) in mice using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS) and in the quantification of lysoPI (LPI) in livers of chronic high-fat diet (HFD)-fed WT and KO mice using liquid chromatography with tandem mass spectrometry (LC-MS-MS) system.
생화학적/생리학적 작용
Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.
Lysophosphatidylinositol (LPI) serve as a bioactive lysophospholipid mediator. It favors mitogenic activity in quiescent fibroblasts. LPI has the ability to block hippocampal neuronal death in conditions of forebrain ischemia.
포장
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-100ug)
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-500ug)
법적 정보
Avanti Research is a trademark of Avanti Polar Lipids, LLC
또한 이 제품과 함께 일반적으로 구입
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
No data available
Flash Point (°C)
No data available
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
이미 열람한 고객
Cancers, 12(1) (2020-01-01)
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.